Ngm Biopharmaceuticals Stock Short Ratio
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
NGM Biopharmaceuticals Company Short Ratio Analysis
NGM Biopharmaceutica's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current NGM Biopharmaceutica Short Ratio | 1.26 X |
Most of NGM Biopharmaceutica's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, NGM Biopharmaceuticals has a Short Ratio of 1.26 times. This is 67.69% lower than that of the Pharmaceuticals sector and 83.0% lower than that of the Health Care industry. The short ratio for all United States stocks is 68.5% higher than that of the company.
NGM Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.NGM Biopharmaceutica is currently under evaluation in short ratio category among its peers.
NGM Fundamentals
Return On Equity | -0.7 | |||
Return On Asset | -0.38 | |||
Operating Margin | (179.78) % | |||
Current Valuation | (36.13 M) | |||
Shares Outstanding | 83.46 M | |||
Shares Owned By Insiders | 21.08 % | |||
Shares Owned By Institutions | 54.16 % | |||
Number Of Shares Shorted | 1.68 M | |||
Price To Earning | (21.12) X | |||
Price To Book | 0.86 X | |||
Price To Sales | 29.10 X | |||
Revenue | 4.42 M | |||
Gross Profit | (125.73 M) | |||
EBITDA | (144.33 M) | |||
Net Income | (142.38 M) | |||
Cash And Equivalents | 297.81 M | |||
Cash Per Share | 3.71 X | |||
Total Debt | 5.38 M | |||
Debt To Equity | 0.03 % | |||
Current Ratio | 7.49 X | |||
Book Value Per Share | 1.79 X | |||
Cash Flow From Operations | (132.2 M) | |||
Short Ratio | 1.26 X | |||
Earnings Per Share | (1.73) X | |||
Target Price | 1.66 | |||
Number Of Employees | 138 | |||
Beta | 1.26 | |||
Market Capitalization | 128.53 M | |||
Total Asset | 168.87 M | |||
Retained Earnings | (724.01 M) | |||
Working Capital | 136.36 M | |||
Current Asset | 330.81 M | |||
Current Liabilities | 43.69 M | |||
Net Asset | 168.87 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
CEOs Directory Screen CEOs from public companies around the world | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |